contact

Prof. Silke Gillessen Sommer

titel Prof. Dr. med.

first name Silke

last name Gillessen Sommer

country Switzerland

phone number ++41 71 494 11 11

fax ++41 71 494 63 25

e-mail silke.gillessen@kssg.ch

2

publications

title

journalpaper/review

Papazoglou D, Wannesson L, Berthold D, Cathomas R, Gillessen SommerS, Rothermundt C, Hasler L, Winterhalder R, Barth A, Mingrone W,Nussbaum C U, von Rohr L, von Burg P, Schmid M, Richner J, BaumannS, Kühne R, Stenner F, Rothschild S I. Enzalutamide in Patients WithCastration-Resistant Prostate Cancer Progressing After Docetaxel:Retrospective Analysis of the Swiss Enzalutamide Named PatientProgram. Clin Genitourin Cancer 2016;.

Cathomas R, Crabb S J, Mark M, Winterhalder R, Rothermundt C, Elliott T,von Burg P, Kenner H, Hayoz S, Vilei S B, Rauch D, Roggero E, MohauptM G, Bernhard J, Manetsch G, Gillessen Sommer S, . Orteronel SwitchMaintenance Therapy in Metastatic Castration Resistant Prostate CancerAfter First-Line Docetaxel: A Multicenter, Randomized, Double-Blind,Placebo-Controlled Trial (SAKK 08/11). Prostate 2016;.

Schmid S, Omlin A, Blum D, Strasser F, Gillessen Sommer S,Rothermundt C. Assessment of Anticancer-Treatment Outcome in Patientswith Metastatic Castration-Resistant Prostate Cancer - Going beyond PSAand Imaging, a Systematic Literature Review. Ann Oncol 2015;.

Rothermundt C, Bailey A, Cerbone L, Eisen T, Escudier B, GillessenSommer S, Grünwald V, Larkin J, McDermott D, Oldenburg J, Porta C,Rini B, Schmidinger M, Sternberg C, Putora P M. Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma-AnalysisUsing Diagnostic Nodes. Oncologist 2015; 20:1028-35.

Gillessen Sommer S, De Santis M, Rothermundt C. On Nonharming: TheDebate Continues in Stage I Testicular Cancer. J Clin Oncol 2015;.

3

publications

title

journalpaper/review

Joerger M, van Schaik R H N, Becker M L, Hayoz S, Pollak M, CathomasR, Winterhalder R, Gillessen Sommer S, Rothermundt C. Multidrug andtoxin extrusion 1 and human organic cation transporter 1 polymorphismsin patients with castration-resistant prostate cancer receiving metformin(SAKK 08/09). Prostate Cancer Prostatic Dis 2015;.

Gillessen Sommer S, Fanti S, Omlin A, panelists and authors of APCCC .Reply to the letter to the editor 'Management of patients with advancedprostate cancer: recommendations of the St Gallen Advanced ProstateCancer Consensus Conference (APCCC) 2015' by Gillessen et al. AnnOncol 2015; 26:2354-5.

Desax M C, Hundsberger T, Rothermundt C, Omlin A, Gillessen SommerS. Restless Legs Syndrome—An Emerging Potential Side Effect ofEnzalutamide: Report of 2 Cases. Clin Genitourin Cancer 2015; 13:e385-6.

Omlin A, Sartor O, Rothermundt C, Cathomas R, De Bono J S, Shen L, SuZ, Gillessen Sommer S. Analysis of Side Effect Profile of Alopecia, NailChanges, Peripheral Neuropathy, and Dysgeusia in Prostate CancerPatients Treated With Docetaxel and Cabazitaxel. Clin Genitourin Cancer2015;.

Rothermundt C, Hader C, Gillessen Sommer S. Successful treatment withan anti-PD-1 antibody for progressing brain metastases in renal cellcancer. Ann Oncol 2015;.

Shao S, Guo T, Koh C C, Gillessen Sommer S, Joerger M, Jochum W,Aebersold R. Minimal sample requirement for highly multiplexed proteinquantification in cell lines and tissues by PCT-SWATH mass spectrometry.Proteomics 2015; 15:3711-21.

4

publications

title

journalpaper/review

Guo T, Kouvonen P, Koh C C, Gillet L C, Wolski W E, Röst H L,Rosenberger G, Collins B C, Blum L C, Gillessen Sommer S, Joerger M,Jochum W, Aebersold R. Rapid mass spectrometric conversion of tissuebiopsy samples into permanent quantitative digital proteome maps. NatMed 2015; 21:407-13.

Fischer S, Gillessen Sommer S, Rothermundt C. Sequence of treatment inlocally advanced and metastatic renal cell carcinoma. Transl Androl Urol2015; 4:310-25.

Gillessen Sommer S, Omlin A, Attard G, de Bono J S, Efstathiou E, FizaziK, Halabi S, Nelson P S, Sartor O, Smith M R, Soule H R, Akaza H, Beer TM, Beltran H, Chinnaiyan A M, Daugaard G, Davis I D, De Santis M, DrakeC G, Eeles R A, Fanti S, Gleave M E, Heidenreich A, Hussain M, James ND, Lecouvet F E, Logothetis C J, Mastris K, Nilsson S, Oh W K, Olmos D,Padhani A R, Parker C, Rubin M A, Schalken J A, Scher H I, Sella A, ShoreN D, Small E J, Sternberg C N, Suzuki H, Sweeney C J, Tannock I F,Tombal B. Management of patients with advanced prostate cancer:recommendations of the St Gallen Advanced Prostate Cancer ConsensusConference (APCCC) 2015. Ann Oncol 2015; 26:1589-604.

Parker C, Gillessen Sommer S, Heidenreich A, Horwich A, ESMOGuidelines Committee . Cancer of the prostate: ESMO Clinical PracticeGuidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26Suppl 5:v69-77.

Fitzpatrick J M, Bellmunt J, Fizazi K, Heidenreich A, Sternberg C N,Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, FinnS P, Fosså S, Gillessen Sommer S, Kellokumpu-Lehtinen P L, Lecouvet FE, Oudard S, de Reijke T M, Robson C N, De Santis M, Seruga B, de WitR. Optimal management of metastatic castration-resistant prostatecancer: highlights from a European Expert Consensus Panel. Eur J Cancer2014; 50:1617-27.

5

publications

title

journalpaper/review

Cathomas R, Bajory Z, Bouzid M, El Ghoneimy A, Gillessen Sommer S,Goncalves F, Kacso G, Kramer G, Milecki P, Pacik D, Tantawy W,Lesniewski-Kmak K. Management of bone metastases in patients withcastration-resistant prostate cancer. Urol Int 2014; 92:377-86.

Schmid S, Fornaro J, Rothermundt C, Omlin A, Brändle M, Rupp N J,Gillessen Sommer S. Abiraterone--what is wrong with the adrenalglands?. Clin Genitourin Cancer 2014; 12:e133-7.

Fizazi K, Abrahamsson P A, Ahlgren G, Bellmunt J, Castellano D, Culine S,de Wit R, Gillessen Sommer S, Gschwend J E, Hamdy F, James N,McDermott R, Miller K, Wiegel T, Wirth M, Tombal B. Achievements andPerspectives in Prostate Cancer Phase 3 Trials from GenitourinaryResearch Groups in Europe: Introducing the Prostate Cancer Consortiumin Europe. Eur Urol 2014;.

Omlin A, Pezaro C, Gillessen Sommer S. Sequential use of noveltherapeutics in advanced prostate cancer following docetaxelchemotherapy. Ther Adv Urol 2014; 6:3-14.

Lorente D, Omlin A, Ferraldeschi R, Pezaro C, Perez R, Mateo J, AltavillaA, Zafeirou Z, Tunariu N, Parker C, Dearnaley D, Gillessen Sommer S, deBono J, Attard G. Tumour responses following a steroid switch fromprednisone to dexamethasone in castration-resistant prostate cancerpatients progressing on abiraterone. Br J Cancer 2014;.

Omlin A, Stienen M N, Brügge D, Fretz C, Gillessen Sommer S,Hundsberger T. Maligne spinale Kompression: Prävention, Erkennungund «State of the Art»-Behandlung. SMF 2014; 14:820-825.

6

publications

title

journalpaper/review

de Bono J S, Piulats J M, Pandha H S, Petrylak D P, Saad F, Aparicio L MA, Sandhu S K, Fong P, Gillessen Sommer S, Hudes G R, Wang T,Scranton J, Pollak M N. Phase II randomized study of figitumumab plusdocetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer. Clin Cancer Res 2014; 20:1925-34.

Rothermundt C, Hayoz S, Templeton A, Winterhalder R, Strebel R T,Bärtschi D, Pollak M, Lui L, Endt K, Schiess R, Rüschoff J H, Cathomas R,Gillessen Sommer S. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). EurUrol 2014; 66:468-74.

Schmid S, Gillessen Sommer S, Binet I, Brändle M, Engeler D, Greiner J,Hader C, Heinimann K, Kloos P, Krek W, Krull I, Stöckli S, Sulz M, vanLeyen K, Weber J, Rothermundt C, Hundsberger T. Management of vonHippel-Lindau Disease: An Interdisciplinary Review. Oncol Res Treat2014; 37:761-771.

Oldenburg J, Aparicio J, Beyer J, Cohn-Cedermark G, Cullen M, Gilligan T,De Giorgi U, De Santis M, de Wit R, Fosså S D, Germà-Lluch J R,Gillessen Sommer S, Haugnes H S, Honecker F, Horwich A, Lorch A,Ondruscaron D, Rosti G, Stephenson A, Tandstad T. Personalizing, notpatronizing: The case for patient autonomy by unbiased presentation ofmanagement options in stage I testicular cancer. Ann Oncol 2014;.

Früh M, Besrour H, Gillessen Sommer S, Joerger M, Hitz F, Savidan A,Cerny T, Ess S. Management of elderly patients with advanced non-smallcell lung cancer: a single-center experience. Chemotherapy 2013;59:42-50.

7

publications

title

journalpaper/review

Laurent J, Touvrey C, Gillessen Sommer S, Joffraud M, Vicari M, BertrandC, Ongarello S, Liedert B, Gallerani E, Beck J, Omlin A, Sessa C,Quaratino S, Stupp R, Gnad-Vogt U S, Speiser D E. T-cell activation bytreatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. J Transl Med 2013; 11:5.

Strebel R T, Sulser T, Schmid H P, Gillessen Sommer S, Fehr M, Huber U,Pless M, Morant R, Winterhalder R, Cathomas R. Multidisciplinary care inpatients with prostate cancer: room for improvement. Support CareCancer 2013; 21:2327-33.

Rothermundt C, Gillessen Sommer S. Angioedema in a renal cell cancerpatient treated with everolimus in combination with an ACE inhibitor. JClin Oncol 2013; 31:e57-8.

Joerger M, Huitema A D R, Koeberle D, Rosing H, Beijnen J H, Hitz F,Cerny T, Schellens J H M, Gillessen Sommer S. Safety and pharmacologyof gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. Cancer Chemother Pharmacol2013; 73:113-24.

Papachristofilou A, Cathomas R, Bedke J, Souchon R, Kolb C, GillessenSommer S. Optimizing treatment of seminoma stage IIA/B step by step.Ann Oncol 2013; 24:2463.

Templeton A, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C,Gautschi O, Borner M, Fechter E, Stenner F, Winterhalder R, Müller B,Schiess R, Wild P J, Rüschoff J H, Thalmann G, Dietrich P Y, Aebersold R,Klingbiel D, Gillessen Sommer S, Swiss Group for Clinical CancerResearch (SAKK) . Phase 2 trial of single-agent everolimus inchemotherapy-naive patients with castration-resistant prostate cancer(SAKK 08/08). Eur Urol 2013; 64:150-8.

8

publications

title

journalpaper/review

Rothermundt C, Gillessen Sommer S. Angioedema in a patient with renalcell cancer treated with everolimus in combination with an angiotensin-converting enzyme inhibitor. J Clin Oncol 2013; 31:e57-8.

Schoenewolf N L, Dummer R, Mihic-Probst D, Moch H, Simcock M,Ochsenbein A, Gillessen Sommer S, Schraml P, von Moos R, Swiss Groupfor Clinical Cancer Research (SAKK) . Detecting BRAF Mutations inFormalin-Fixed Melanoma: Experiences with Two State-of-the-ArtTechniques. Case Rep Oncol 2012; 5:280-9.

Gillessen Sommer S, Gross-Goupil M, Zucali P, Horwich A, Germa-Lluch J,Kollmansberger C, Stoiber F, Fléchon A, Oechsle K. 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapyseminoma residual lesions: a retrospective validation of the SEMPET trial.Ann Oncol 2012; 23:59-64.

Omlin A, Gillessen Sommer S. [Inhibitors of androgen and estrogenbiosynthesis in castration-resistant prostate cancer]. Urologe A 2012;51:8-14.

Cathomas R, Rothermundt C, Klingbiel D, Bubendorf L, Jaggi R, BetticherD C, Brauchli P, Cotting D, Droege C, Winterhalder R, Siciliano D,Berthold D R, Pless M, Schiess R, von Moos R, Gillessen Sommer S, SwissGroup for Clinical Cancer Research SAKK . Efficacy of cetuximab inmetastatic castration-resistant prostate cancer might depend on EGFRand PTEN expression: results from a phase II trial (SAKK 08/07). ClinCancer Res 2012; 18:6049-57.

Kälin M, Cima I, Schiess R, Fankhauser N, Powles T, Wild P, Templeton A,Cerny T, Aebersold R, Krek W, Gillessen Sommer S. Novel prognosticmarkers in the serum of patients with castration-resistant prostatecancer derived from quantitative analysis of the pten conditionalknockout mouse proteome. Eur Urol 2011; 60:1235-43.

9

publications

title

journalpaper/review

Cathomas R, Berthold D, Gillessen Sommer S, Recker F, Stenner F,Strebel R, Sulser T, Zwahlen D, Schmid H P. Das Prostatakarzinom imWandel. Grundpfeiler der Diagnostik, Behandlung und Interdisziplinarität.Schweiz Med Forum 2011; 11:759-63.

Bachner M, Loriot Y, Gross-Goupil M, Zucali P A, Horwich A, Germa-LluchJ R, Kollmannsberger C, Stoiber F, Fléchon A, Oechsle K, GillessenSommer S, Oldenburg J, Cohn-Cedermark G, Daugaard G, Morelli F, SellaA, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, De Santis M. 2-¹fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) forpostchemotherapy seminoma residual lesions: a retrospective validationof the SEMPET trial. Ann Oncol 2011; 23:59-64.

Cima I, Schiess R, Wild P, Kälin M, Schüffler P, Lange V, Picotti P, OssolaR, Templeton A, Schubert O, Fuchs T, Leippold T, Wyler S, Zehetner J,Jochum W, Buhmann J, Cerny T, Moch H, Gillessen Sommer S, AebersoldR, Krek W. Cancer genetics-guided discovery of serum biomarkersignatures for diagnosis and prognosis of prostate cancer. Proc Natl AcadSci USA 2011; 108:3342-7.

Hartmann M, Krege S, Souchon R, De Santis M, Gillessen Sommer S,Cathomas R, Interdisziplinäre Arbeitsgruppe Hodentumore . [Follow-up oftesticular germ cell cancer patients: interdisciplinary evidence-basedrecommendations]. Urologe A 2011; 50:830-5.

Cathomas R, Hartmann M, Krege S, Souchon R, Lorch A, Mayer F, DeSantis M, Gillessen Sommer S, Interdisziplinäre ArbeitsgruppeHodentumore . Interdisciplinary evidence-based recommendations for thefollow-up of testicular germ cell cancer patients. Onkologie 2011;34:59-64.

10

publications

title

journalpaper/review

Souchon R, Hartmann M, Krege S, Lorch A, Mayer F, De Santis M,Gillessen Sommer S, Beyer J, Cathomas R. Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatoustesticular germ cell cancer patients. Strahlenther Onkol 2011;187:158-66.

Omlin A, Kälin M, Templeton A, Gillessen Sommer S, Graf H J,Rothermundt C. Metastasiertes Prostatakarzinom –Behandlungsmöglichkeiten nach der Hormontherapie. Swiss MedicalForum 2010; 10:483-485.

Böhm S, Hess D, Gillessen Sommer S, Brändle M. Improved glycemiccontrol with the multi-receptor tyrosine kinase inhibitor pazopanib.Diabetes Care 2010; 33:e82.

Cathomas R, Helbling D, Stenner F, Rothermundt C, Rentsch C, Shahin O,Seifert H H, Zaugg K, Lorch A, Mayer F, Beyer J, De Santis M, GillessenSommer S. Interdisciplinary evidence-based recommendations for thefollow-up of testicular cancer patients: a joint effort. Swiss Med Wkly2010; 140:356-69.

Gillessen Sommer S, Powles T, Lim L, Wilson P, Shamash J. Low-doseinduction chemotherapy with Baby-BOP in patients with metastatic germ-cell tumours does not compromise outcome: a single-centre experience.Ann Oncol 2010; 21:1589-93.

Powles T, Chowdhury S, Shamash J, Bazeos A, Gillessen Sommer S,Saunders N, Lim L, Sarwar N, Sadev A, Wilson P, Nathan P, Boleti K,Peters J, Agrawal S. Increased haematopoietic progenitor cells areassociated with poor outcome in patients with metastatic renal cancertreated with sunitinib. Ann Oncol 2010;.

11

publications

title

journalpaper/review

Gillessen Sommer S, Templeton A, Marra G, Kuo Y F, Valtorta E,Shahinian V B. Risk of colorectal cancer in men on long-term androgendeprivation therapy for prostate cancer. J Natl Cancer Inst 2010;102:1760-70.

Fokt R M, Templeton A, Gillessen Sommer S, Öhlschlegel C, Schmid H P.Prostatic metastasis of renal cell carcinoma successfully treated withsunitinib. Urol Int 2009; 83:122-4.

Rothermundt C, Omlin A, Gillessen Sommer S. 'Sunitinib withdrawalphenomenon' or spontaneous regression in renal cell cancer. Annals ofoncology : official journal of the European Society for Medical Oncology /ESMO 2009; 20:1144-6.

Fehr M, Templeton A, Cogliatti S B, Aebersold F, Egli F, Gillessen SommerS, Cathomas R. Primary manifestation of small lymphocytic lymphoma inthe prostate. Onkologie 2009; 32:586-8.

Omlin A, D'Addario G, Gillessen Sommer S, Cerny T, Früh M. Activity ofpemetrexed against brain metastases in a patient with adenocarcinomaof the lung. Lung cancer (Amsterdam, Netherlands) 2009; 65:383-4.

Templeton A, Marra G, Valtorta E, Heinimann K, Müller H, GillessenSommer S. Concordant colon tumors in monozygotic twins previouslytreated for prostate cancer. Familial cancer 2009; 8:167-71.

Escudier B, Roigas J, Gillessen Sommer S, Harmenberg U, Srinivas S,Mulder S F, Fountzilas G, Peschel C, Flodgren P, Maneval E C, Chen I,Vogelzang N J. Phase II study of sunitinib administered in a continuousonce-daily dosing regimen in patients with cytokine-refractory metastaticrenal cell carcinoma. Journal of clinical oncology : official journal of theAmerican Society of Clinical Oncology 2009; 27:4068-75.

12

publications

title

journalpaper/review

Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M,Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder P H M, De Santis M, deWit M, de Wit R, Derigs H G, Dieckmann K P, Dieing A, Droz J P, FennerM, Fizazi K, Flechon A, Fosså S D, del Muro X G, Gauler T, Geczi L, Gerl A,Germa-Lluch J R, Gillessen Sommer S, Hartmann J T, Hartmann M,Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann K U, Kollmannsberger C,Kuczyk M, Laguna P, Galvis O L, Loy V, Mason M D, Mead G M, Mueller R,Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof G O N, Paz-Ares L,Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R,Scheiderbauer J, Schmelz H U, Schmidberger H, Schmoll H J, Schrader M,Sedlmayer F, Skakkebaek N E, Sohaib A, Tjulandin S, Warde P,Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von derMaase H. European consensus conference on diagnosis and treatment ofgerm cell cancer: a report of the second meeting of the European GermCell Cancer Consensus Group (EGCCCG): part II. European urology2008; 53:497-513.

13

publications

title

journalpaper/review

Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M,Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder P H M, De Santis M, deWit M, de Wit R, Derigs H G, Dieckmann K P, Dieing A, Droz J P, FennerM, Fizazi K, Flechon A, Fosså S D, del Muro X G, Gauler T, Geczi L, Gerl A,Germa-Lluch J R, Gillessen Sommer S, Hartmann J T, Hartmann M,Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann K U, Kollmannsberger C,Kuczyk M, Laguna P, Galvis O L, Loy V, Mason M D, Mead G M, Mueller R,Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof G O N, Ares L P,Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R,Scheiderbauer J, Schmelz H U, Schmidberger H, Schmoll H J, Schrader M,Sedlmayer F, Skakkebaek N E, Sohaib A, Tjulandin S, Warde P,Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von derMaase H. European consensus conference on diagnosis and treatment ofgerm cell cancer: a report of the second meeting of the European GermCell Cancer Consensus group (EGCCCG): part I. European urology 2008;53:478-96.

von Moos R, Strasser F, Gillessen Sommer S, Zaugg K. Metastatic bonepain: treatment options with an emphasis on bisphosphonates.Supportive care in cancer : official journal of the Multinational Associationof Supportive Care in Cancer 2008; 16:1105-15.

Templeton A, Brändle M, Cerny T, Gillessen Sommer S. Remission ofdiabetes while on sunitinib treatment for renal cell carcinoma. Annals ofoncology : official journal of the European Society for Medical Oncology /ESMO 2008; 19:824-5.

Templeton A, Hofer S, Töpfer M, Sommacal A, Fretz C, Cerny T, GillessenSommer S. Extraneural spread of glioblastoma--report of two cases.Onkologie 2008; 31:192-4.

14

publications

title

journalpaper/review

Joerger M, Henz S, Zaunbauer W, Cerny T, Cogliatti S B, GillessenSommer S. CT-diagnosed mesenteric alterations in patients with non-Hodgkin's lymphoma: a population-based study. Onkologie 2008;31:514-9.

Strasser F, Demmer-Steingruber R, Böhme C, Schmitz S F H, ThürlimannB, Cerny T, Gillessen Sommer S. Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: arandomized, placebo-controlled, double-blind study. The Oncologist2008; 13:337-46.

Früh M, Gillessen Sommer S, Cerny T, Demmer-Steingruber R, D'AddarioG. Two-weekly gemcitabine fixed dose rate and oxaliplatin combinationchemotherapy for advanced non-small-cell lung cancer. Lung cancer(Amsterdam, Netherlands) 2008; 62:344-50.

Steinbild S, Mross K, Frost A, Morant R, Gillessen Sommer S, Dittrich C,Strumberg D, Hochhaus A, Hanauske A R, Edler L, Burkholder I, ScheulenM. A clinical phase II study with sorafenib in patients with progressivehormone-refractory prostate cancer: a study of the CESAR CentralEuropean Society for Anticancer Drug Research-EWIV. British journal ofcancer 2007; 97:1480-5.

Cathomas R, Boehm T, Pestalozzi B C, Gillessen Sommer S, von Moos R.Feasibility of using cetuximab and bevacizumab in a patient withcolorectal cancer and terminal renal failure. Oncology 2007; 72:209-10.

Gillessen Sommer S, Graf L, Korte W, Cerny T. Macrocytosis andcobalamin deficiency in patients treated with sunitinib. The New Englandjournal of medicine 2007; 356:2330-1.

15

publications

title

journalpaper/review

Enzler T, Gillessen Sommer S, Dougan M, Allison J P, Neuberg D, Oble DA, Mihm M, Dranoff G. Functional deficiencies of granulocyte-macrophagecolony stimulating factor and interleukin-3 contribute to insulitis anddestruction of beta cells. Blood 2007; 110:954-61.

Rohr L, Klaeser B, Joerger M, Kluckert J T, Cerny T, Gillessen Sommer S.Increased pulmonary FDG Uptake in Bleomycin-associated pneumonitis.Onkologie 2007;320-323.

Templeton A, Gillessen Sommer S. Sinnvoll?. Schweiz Med Forum 2007;7:469.

von Rohr L, Klaeser B, Joerger M, Kluckert T, Cerny T, Gillessen SommerS. Increased pulmonary FDG uptake in bleomycin-associatedpneumonitis. Onkologie 2007; 30:320-3.

Schlaeppi M, Korte W, von Moos R, Cerny T, Gillessen Sommer S.Successful treatment of acute disseminated intravascular coagulation in apatient with metastatic melanoma. Onkologie 2006; 29:531-3.

Gillessen Sommer S, Strasser F. [Treatment possibilities for patients withadvanced prostate cancer]. Therapeutische Umschau. Revuethérapeutique 2006; 63:157-62.

Jermann M, Stahel R A, Salzberg M, Cerny T, Joerger M, GillessenSommer S, Morant R, Egli F, Rhyner K, Bauer J A, Pless M. A phase II,open-label study of gefitinib (IRESSA) in patients with locally advanced,metastatic, or relapsed renal-cell carcinoma. Cancer chemotherapy andpharmacology 2006; 57:533-9.

Waeckerle-Men Y, Uetz-Von Allmen E, Fopp M, von Moos R, Böhme C,Schmid H P, Ackermann D, Cerny T, Ludewig B, Groettrup M, GillessenSommer S. Dendritic cell-based multi-epitope immunotherapy ofhormone-refractory prostate carcinoma. Cancer immunology,immunotherapy : CII 2006; 55:1524-33.

16

publications

title

journalpaper/review

Waeckerle-Men Y, Allmen E U V, von Moos R, Classon B J, Scandella E,Schmid H P, Ludewig B, Groettrup M, Gillessen Sommer S. Dendritic cellsgenerated from patients with androgen-independent prostate cancer arenot impaired in migration and T-cell stimulation. The Prostate 2005;64:323-31.

Wuermli L, Joerger M, Henz S, Schmid H P, Riesen W F, Thomas G, KrekW, Cerny T, Gillessen Sommer S. Hypertriglyceridemia as a possible riskfactor for prostate cancer. Prostate cancer and prostatic diseases 2005;8:316-20.

Würmli L, Joerger M, Henz S, Schmid H P, Riesen W F, Thomas G, Krek W,Cerny T, Gillessen Sommer S. Hypertriglyceridemia as a possible riskfactor for prostate cancer. Prostate Cancer Prostatic Dis 2005;8:316-320.

Joerger M, Neumann H P H, Gillessen Sommer S. Von Hippel-Lindaudisease--a rare disease important to recognize. Onkologie 2005;28:159-63.

Nieuwenhuis E E S, Gillessen Sommer S, Scheper R J, Exley M A,Taniguchi M, Balk S P, Strominger J L, Dranoff G, Blumberg R S, Wilson SB. CD1d and CD1d-restricted iNKT-cells play a pivotal role in contacthypersensitivity. Experimental dermatology 2005; 14:250-8.

Cerny T, Hitz F, Gillessen Sommer S. [Mabthera for treatment ofmalignant lymphoma]. Therapeutische Umschau. Revue thérapeutique2004; 61:379-83.

Joerger M, Warzinek T, Klaeser B, Kluckert J T, Schmid H P, GillessenSommer S. Major tumor regression after paclitaxel and carboplatinpolychemotherapy in a patient with advanced penile cancer. Urology2004; 63:778-80.

17

publications

title

journalpaper/review

Morant R, Bernhard J, Dietrich D, Gillessen Sommer S, Bonomo M,Borner M, Bauer J, Rochlitz C, Cerny T, Wernli M, Gschwend A,Hanselmann S, Hering F, Schmid H P. Capecitabine in hormone-resistantmetastatic prostatic carcinoma - a phase II trial. British journal of cancer2004; 90:1312-7.

Scandella E, Men Y, Legler D F, Gillessen Sommer S, Prikler L, Ludewig B,Groettrup M. CCL19/CCL21-triggered signal transduction and migration ofdendritic cells requires prostaglandin E2. Blood 2004; 103:1595-601.

Joerger M, Warzinek T, Klaeser B, Kluckert J T, Schmid H P, GillessenSommer S. Major tumor regression afrer paclitaxel and carboplatinpolychemotherapy in a patient with advanced penile cancer. Urology2004; 63:778-780.

Waeckerle-Men Y, Scandella E, Uetz-Von Allmen E, Ludewig B, GillessenSommer S, Merkle H P, Gander B, Groettrup M. Phenotype and functionalanalysis of human monocyte-derived dendritic cells loaded withbiodegradable poly(lactide-co-glycolide) microspheres forimmunotherapy. Journal of immunological methods 2004; 287:109-24.

Prikler L, Scandella E, Men Y, Engeler D, Diener P A, Gillessen Sommer S,Ludewig B, Schmid H P. Adaptive Immuntherapie des fortgeschrittenenProstatakarzinoms: Cancer Testis Antigene (CTA) als möglicheZielantigene. Aktuel Urol 2004; 35:326-330.

Prikler L, Scandella E, Men Y, Engeler D S, Diener P A, Gillessen SommerS, Ludewig B, Schmid H P. [Adaptive immunotherapy of the advancedprostate cancer - cancer testis antigen (CTA) as possible targetantigens]. Aktuelle Urologie 2004; 35:326-30.

18

publications

title

journalpaper/review

Enzler T, Gillessen Sommer S, Manis J P, Ferguson D, Fleming J, Alt F W,Mihm M, Dranoff G. Deficiencies of GM-CSF and interferon gamma linkinflammation and cancer. The Journal of experimental medicine 2003;197:1213-9.

von Moos R, Stolz R, Cerny T, Gillessen Sommer S. Thalidomide: fromtragedy to promise. Swiss medical weekly : official journal of the SwissSociety of Infectious Diseases, the Swiss Society of Internal Medicine, theSwiss Society of Pneumology 2003; 133:77-87.

Gillessen Sommer S, Naumov Y N, Nieuwenhuis E E S, Exley M A, Lee FS, Mach N, Luster A D, Blumberg R S, Taniguchi M, Balk S P, Strominger JL, Dranoff G, Wilson S B. CD1d-restricted T cells regulate dendritic cellfunction and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proceedings of the NationalAcademy of Sciences of the United States of America 2003; 100:8874-9.

Soiffer R, Hodi F S, Haluska F, Jung K, Gillessen Sommer S, Singer S,Tanabe K, Duda R, Mentzer S, Jaklitsch M, Bueno R, Clift S, Hardy S,Neuberg D, Mulligan R, Webb I, Mihm M, Dranoff G. Vaccination withirradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated genetransfer augments antitumor immunity in patients with metastaticmelanoma. Journal of clinical oncology : official journal of the AmericanSociety of Clinical Oncology 2003; 21:3343-50.

Scandella E, Men Y, Gillessen Sommer S, Förster R, Groettrup M.Prostaglandin E2 is a key factor for CCR7 surface expression andmigration of monocyte-derived dendritic cells. Blood 2002; 100:1354-61.

19

publications

title

journalpaper/review

Joerger M, Öhlschlegel C, Cerny T, Gillessen Sommer S. Postradiationhigh-grade myofibroblastic sarcoma of the prostate -- a rare entity ofprostatic tumors -- responding to liposomal Doxorubicin. Onkologie 2002;25:558-61.

Cerny T, Gillessen Sommer S. Advances in the treatment of non-Hodgkin's lymphoma. Annals of oncology : official journal of theEuropean Society for Medical Oncology / ESMO 2002; 13 Suppl 4:211-6.

Gillessen Sommer S, Groettup M, Cerny T. The proteasome, a new targetfor cancer therapy. Onkologie 2002; 25:534-9.

Teshima T, Mach N, Hill G R, Pan L, Gillessen Sommer S, Dranoff G,Ferrara J L. Tumor cell vaccine elicits potent antitumor immunity afterallogeneic T-cell-depleted bone marrow transplantation. Cancer research2001; 61:162-71.

Tomasson M H, Williams I R, Li S, Kutok J, Cain D, Gillessen Sommer S,Dranoff G, Van Etten R A, Gilliland D G. Induction of myeloproliferativedisease in mice by tyrosine kinase fusion oncogenes does not requiregranulocyte-macrophage colony-stimulating factor or interleukin-3. Blood2001; 97:1435-41.

Gillessen Sommer S, Mach N, Small C, Mihm M, Dranoff G. Overlappingroles for granulocyte-macrophage colony-stimulating factor andinterleukin-3 in eosinophil homeostasis and contact hypersensitivity.Blood 2001; 97:922-8.

Li S, Gillessen Sommer S, Tomasson M H, Dranoff G, Gilliland D G, VanEtten R A. Interleukin 3 and granulocyte-macrophage colony-stimulatingfactor are not required for induction of chronic myeloid leukemia-likemyeloproliferative disease in mice by BCR/ABL. Blood 2001; 97:1442-50.

20

publications

title

journalpaper/review

Mach N, Gillessen Sommer S, Wilson S B, Sheehan C, Mihm M, DranoffG. Differences in dendritic cells stimulated in vivo by tumors engineeredto secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer research 2000; 60:3239-46.

Presky D H, Minetti L J, Gillessen Sommer S, Wilkinson V L, Wu C Y,Gubler U, Chizzonite R, Gately M K. Analysis of the multiple interactionsbetween IL-12 and the high affinity IL-12 receptor complex. Journal ofimmunology (Baltimore, Md. : 1950) 1998; 160:2174-9.

Skoda R C, Tichelli A, Tyndall A, Hoffmann T, Gillessen Sommer S,Gratwohl A. Autologous peripheral blood stem cell transplantation in apatient with chronic autoimmune thrombocytopenia. British journal ofhaematology 1997; 99:56-7.

Gately M K, Carvajal D M, Connaughton S E, Gillessen Sommer S, WarrierR R, Kolinsky K D, Wilkinson V L, Dwyer C M, Higgins G F, Podlaski F J,Faherty D A, Familletti P C, Stern A S, Presky D H. Interleukin-12antagonist activity of mouse interleukin-12 p40 homodimer in vitro andin vivo. Annals of the New York Academy of Sciences 1996; 795:1-12.

Presky D H, Minetti L J, Gillessen Sommer S, Gubler U, Chizzonite R,Stern A S, Gately M K. Evidence for multiple sites of interaction betweenIL-12 and its receptor. Annals of the New York Academy of Sciences1996; 795:390-3.

Gillessen Sommer S, Carvajal D, Ling P, Podlaski F J, Stremlo D L,Familletti P C, Gubler U, Presky D H, Stern A S, Gately M K. Mouseinterleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist.European journal of immunology 1995; 25:200-6.

21

publications

title

journalpaper/review

Laudiero L B, Aloe L, Levi-Montalcini R, Buttinelli C, Schilter D, GillessenSommer S, Otten U. Multiple sclerosis patients express increased levelsof beta-nerve growth factor in cerebrospinal fluid. Neuroscience letters1992; 147:9-12.

Sartor O, Gillessen Sommer S. Treatment sequencing in metastaticcastrate-resistant prostate cancer. Asian J Androl 16:426-31.

presentation von Moos R, Seifert B, Ochsenbein A, Cathomas R, Schlaeppi M, GillessenSommer S, Schuller J, Michielin O, Goldinger S, & Dummer R (2009).Temozolomide combined with bevacizumab in metastatic melanoma. Amulticenter phase II trial (SAKK 50/07). Presented at ECCO / ESMO,Berlin.

22

projects

title status

A Randomized multicenter phase III trial comparingenzalutamide vs. a combination of Ra223 and enzalutamide inasymptomatic or mildly symptomatic castration resistantprostate cancer patients metastatic to bone. PEACE III

ongoing- followup

An open-label, multicohort, phase II study of MPDL3280A inadvanced solid tumors

ongoing- followup

23

projects

title status

A phase III, open-label, multicenter, randomized study toinvestigate the efficacy and safety of MPDL3280A (ANTI−PD-L1ANTIBODY) compared with chemotherapy in patients withlocally advanced or metastatic urothelial bladder cancer afterfailure with platinum-containing chem-otherapy. GO29294

ongoing- followup

SINGLE ARM OPEN LABLE PHASE II PILOT STUDY OFCARBOPLATIN

scheduled

SAKK 63/12 Prospective cohort study with collection of clinicaldata and serum of patients with prostate disease

ongoing- followup

Prevention of symptomatic skeletal events with denosumabadministered every 4 weeks versus every 12 weeks: Anoninferiority phase III trial (SAKK 96/12, REDUSE)

ongoing- followup

Swiss Austrian German Testicular Cancer Cohort Study – SAGTCCS

ongoing- followup

24

projects

title status

Impact of the addition of metformin to abiraterone inmetastatic castration-resistant prostate cancer patientsprogressing on abiraterone treatment (MetAb-Pro): A phase IIpilot study

ongoing- followup

Serum and tissue biomarkers in patients with early andadvanced-stage renal-cell carcinoma

automat-icallyclosed

Cytochrom p450 3A4 and 1A2 phenotyping for theindividualization of treatment with sunitinib or erlotinib incancer patients

automat-icallyclosed

Orteronel maintenance therapy in patients with metastatic cas-tration resistant prostate cancer and non-progressive diseaseafter first-line docetaxel therapy: A multicenter randomizeddou-ble-blind placebo-controlled phase III trial

ongoing- followup

25

projects

title status

Description of relapse in frequency and accompanying factorsin germ cell cancer patients – an observational study

aborted

26

projects

title status

A phase I / II, open-label, multiple-dose study to evaluate thesafety, tolerability, pharmacokinetics and pharmacodynamics ofVT-464 in chemotherapy-naïve patients with castration-refractory prostate cancer. Sponsor:

ongoing- followup

27

projects

title status

An open-label, randomized, multi-center, Phase III study tocompare the safety and efficacy of TKI258 versus sorafenib inpatients with metastatic renal cell carcinoma after failure ofanti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies

automat-icallyclosed

STAMPEDE: Systemic Therapy in Advancing or MetastaticProstate cancer: Evaluation of Drug Efficacy a 5-stage 6-armrandomized controlled trial

ongoing- followup

Metformin in castration resistant prostate cancer. A multicenterphase II trial

completed

SAKK 08/08: Everolimus als Erstlinienbehandlung desKastrationsrefraktären Prostatakarzinoms – Einemultizentrische Phase II Studie

completed

28

projects

title status

Multiepitop Imfpung von Grad III/IV Melanompatienten mitdendritischen Zellen: Bedeutung von Peptidaffinität und -dichtefür die optimale Generierung von tumorspezifischenzytotoxischen T-Lymphozyten

completed

29

projects

title status

A Phase 2, randomized, non-comparative, two-arm open label,multiple-center study of CP-751,871 in combination withDocetaxel/Prednisone in chemotherapy-naive (Arm A) andDocetaxel/Prednisone refractory (Arm B) patients with hormoneinsensitive prostate cancer

completed

Selectikine plus and minus low dose cyclophosphamide inpatients with advanced B cell Non Hodkin Lymphoma and solidtumours

automat-icallyclosed